Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:22 AM
Ignite Modification Date:
2025-12-25 @ 1:22 AM
NCT ID:
NCT06651593
Brief Summary:
To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.
Detailed Description:
Primary Objective
* To identify biomarkers:
* Related to the mechanism of action of SAR444881 alone and in combination with cemiplimab in participants with solid tumors
* Predictive of response/survival and resistance to the combination of SAR444881 and cemiplimab in participants with solid tumors
* To evaluate the association of biomarkers with response/survival and resistance\*:
* Objective response rate (ORR)
* Clinical benefit rate (CBR)
* Progression-free survival (PFS)
* Overall survival (OS)
Secondary Objectives
* To evaluate the efficacy of the SAR444881 and cemiplimab combination
* To determine the safety and tolerability of the SAR444881 and cemiplimab combination
Study:
NCT06651593
Study Brief:
Protocol Section:
NCT06651593